Recombinant meningococcal PorA protein, expressed using a vector system with potential for human vaccination, induces a bactericidal immune response

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1564-1569

  Humphries, Holly E ^a   Williams, Jeannette N ^a   Christodoulides, Myron ^a   Heckels, John E ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Immunogenicity; Neisseria meningitidis; Recombinant PorA

Indexed keywords

ANTISERUM; LIPOSOME; MENINGOCOCCUS VACCINE; PORIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PURIFICATION; EXPRESSION VECTOR; IMMUNOGENICITY; MICELLE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS;

ANIMALS; BLOOD BACTERICIDAL ACTIVITY; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; LIPOSOMES; MENINGOCOCCAL INFECTIONS; MICE; MICE, INBRED BALB C; MICELLES; NEISSERIA MENINGITIDIS; PORINS; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 1842456039     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.042     Document Type: Article

References (34)

1. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:2002;717-722.
2. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;ii:355-7.
3. van der Ley P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:1991;2963-2971.
4. Idanpaan-Heikkila I., Hoiby E.A., Chattopadhyay P., Airaksinen U., Michaelsen T.M., Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol. 43:1995;335-343.
5. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A.et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:1995;4642-4652.
6. Peeters C.M., Rumke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M.et al. Phase-i clinical-trial with a hexavalent pora containing meningococcal outer-membrane vesicle vaccine. Vaccine. 14:1996;1009-1015.
7. Arigita C., Kersten G.A., Hazendonk T., Hennink W.E., Crommelin D.A., Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine. 21(9-10):2003;950-960.
8. Ward S.J., Scopes D.A., Christodoulides M., Clarke I.N., Heckels J.E. Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb. Pathol. 21:1996;499-512.
9. Christodoulides M., Brooks J.L., Rattue E., Heckels J.E. Immunisation with recombinant class 1 outer membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology. 144:1998;3027-3037.
10. Qi H.L., Tai J.Y., Blake M.S. Expression of large amounts of neisserial porin proteins in Escherichia coli and refolding of the proteins into native trimers. Infect. Immun. 62:1994;2432-2439.
11. Jolley K., Appleby L., Wright J.C., Christodoulides M., Heckels J.E. Immunisation with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect. Immun. 69:2001;3809-3916.
12. Wright J.C., Williams J.N., Christodoulides M., Heckels J.E. Immunisation with recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect. Immun. 70:2002;4028-4034.
13. Idanpaan-Heikkila I., Wahlstrom E., Muttilainen S., Nurminen M., Kayhty H., Sarvas M.et al. Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100. Vaccine. 14:1996;886-891.
14. Christodoulides M, Jolley K, Heckels JE. In: Pollard AJ, Maiden MCJ, editors. Meningococcal vaccines. Recombinant proteins in vaccine development. Totowa, NJ: Humana Press; 2001. p. 167-80.
15. Humphries H.E., Christodoulides M., Heckels J.E. Expression of the Class 1 outer-membrane protein of Neisseria meningitidis in Escherichia coli and purification using a self-cleavable affinity tag. Protein Expr. Purif. 26:2002;243-248.
16. McGuinness B.T., Barlow A.K., Clarke I.N., Farley J.E., Anilionis A., Poolman J.T.et al. Deduced amino acid sequences of class 1 protein (porA) from 3 strains of Neisseria meningitidis: synthetic peptides define the epitopes responsible for serosubtype specificity. J. Exp. Med. 171:1990;1871-1882.
17. McGuinness B.T., Lambden P.R., Heckels J.E. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol. 7:1993;505-514.
18. Caugant DA, Wedege E, editors. Recombinant NspA incorporated into liposomal vesicles induces functional antibodies. Oslo, Norway: Norwegian Institute of Public Health; 2002. p. 134.
19. McGuinness B.T., Clarke I.N., Lambden P.R., Barlow A.K., Poolman J.T., Jones D.M.et al. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet. 337:1991;514-517.
20. Christodoulides M., McGuinness B.T., Heckels J.E. Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunisation with a cyclic peptide. J. Gen. Microbiol. 139:1993;1729-1738.
21. van der Voort E.M.R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H.et al. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64(7):1996;2745-2751.
22. Wedege E., Froholm L.O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:1986;571-578.
23. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H.et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
24. de Kleijn E., Vermont C., Kuipers B., van Dijken H., Runke H.et al. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine. 20(3-4):2001;352-358.
25. Muttilainen S., Butcher S.J., Runeberg K., Nurminen M., Idanpaan-Heikkila I., Wahlstrom E.et al. Heterologous production of the P1 porin of Neisseria meningitidis in Bacillus subtilis: The effect of an N-terminal extension on the presentation of native-like epitopes. Microb. Pathol. 18:1995;365-371.
26. Jansen C., Kuipers B., van der Biezen J., de Cock H., van der Ley P., Tommassen J. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 27:2000;227-233.
27. Wetzler L.M., Blake M.S., Barry K., Gotschlich E.C. Gonococcal porin vaccine evaluation: comparison of por proteosomes, liposomes, and blebs isolated from rmp deletion mutants. J. Infect. Dis. 166:1992;551-555.
28. Wetzler LM, Blake MS, Gotschlich EC. Protein-1 (Por) of Neisseria gonorrhoeae as an immunogen: liposomes, proteosomes, and the lack of blocking antibodies. Trans Assoc Am Physicians 1989;102:78-90.
29. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1307-1326.
30. Guttormsen H.K., Wetzler L.M., Solberg C.O. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect. Immun. 62:1994;1437-1443.
31. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B.et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195(11):2002;1445-1454.
32. Martin D., Brodeur B.R., Hamel J., Conture F., de Alwis U., Lian Z.et al. Candidate Neisseria meningitidis NspA vaccine. J. Biotechnol. 83(1-2):2000;27-31.
33. West D., Reddin K., Matheson M., Heath R., Funnell S., Hudson M.et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. 69(3):2001;1561-1567.
34. Lissolo L., Maitrewilmotte G., Dumas P., Mignon M., Danve B., Quentin-Millet M.J. Evaluation of transferrin binding protein 2 within the transferrin binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63(3):1995;884-890.